Cencora Management

Management criteria checks 2/4

Cencora's CEO is Bob Mauch, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is $7.70M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth €7.31M. The average tenure of the management team and the board of directors is 2.5 years and 9.5 years respectively.

Key information

Bob Mauch

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage12.7%
CEO tenure2.1yrs
CEO ownership0.02%
Management average tenure2.5yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Mauch's remuneration changed compared to Cencora's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$2b

Jun 30 2024n/an/a

US$2b

Mar 31 2024n/an/a

US$2b

Dec 31 2023n/an/a

US$2b

Sep 30 2023US$8mUS$975k

US$2b

Jun 30 2023n/an/a

US$2b

Mar 31 2023n/an/a

US$2b

Dec 31 2022n/an/a

US$2b

Sep 30 2022US$6mUS$850k

US$2b

Jun 30 2022n/an/a

US$2b

Mar 31 2022n/an/a

US$2b

Dec 31 2021n/an/a

US$2b

Sep 30 2021US$6mUS$800k

US$2b

Jun 30 2021n/an/a

-US$4b

Mar 31 2021n/an/a

-US$4b

Dec 31 2020n/an/a

-US$3b

Sep 30 2020US$4mUS$700k

-US$3b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019n/an/a

US$649m

Sep 30 2019US$4mUS$675k

US$855m

Jun 30 2019n/an/a

US$956m

Mar 31 2019n/an/a

US$930m

Dec 31 2018n/an/a

US$1b

Sep 30 2018US$3mUS$675k

US$2b

Compensation vs Market: Bob's total compensation ($USD7.70M) is above average for companies of similar size in the German market ($USD4.77M).

Compensation vs Earnings: Bob's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Bob Mauch (57 yo)

2.1yrs

Tenure

US$7,697,850

Compensation

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...


Leadership Team

NamePositionTenureCompensationOwnership
Steven Collis
Executive Chairman13.5yrsUS$17.51m0.16%
€ 72.2m
Robert Mauch
President2.1yrsUS$7.70m0.016%
€ 7.3m
James Cleary
Executive VP & CFO6yrsUS$5.45m0.061%
€ 27.9m
Elizabeth Campbell
Executive VP & Chief Legal Officer3.2yrsUS$4.03m0.0060%
€ 2.7m
Lazarus Krikorian
Senior VP12.8yrsno data0.012%
€ 5.4m
Pawan Verma
Executive VPless than a yearno datano data
Bennett Murphy
Senior Vice President of Investor Relationsno datano datano data
Jennifer Dubas
Senior VP & Chief Compliance Officerno datano datano data
Silvana Battaglia
Executive VP & Chief Human Resources Officer5.8yrsUS$3.48m0.0071%
€ 3.3m
Richard Tremonte
EVP & President of U.S. Pharmaceuticalsless than a yearno datano data
Ann Anaya
Senior VP and Chief Diversity Equity & Inclusion Officer2.8yrsno datano data
Juan Guerra
EVP & President of International Business Groupless than a yearno datano data

2.5yrs

Average Tenure

57yo

Average Age

Experienced Management: ABG's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Collis
Executive Chairman13.5yrsUS$17.51m0.16%
€ 72.2m
Robert Mauch
Presidentless than a yearUS$7.70m0.016%
€ 7.3m
Lauren Tyler
Independent Director1.1yrsno datano data
Richard Gochnauer
Independent Director16.2yrsUS$300.10k0.011%
€ 5.3m
Mark M. Durcan
Lead Independent Director9.2yrsUS$380.05k0.010%
€ 4.6m
Lon Greenberg
Independent Director11.5yrsUS$332.60k0.0057%
€ 2.6m
Kathleen Hyle
Independent Director14.5yrsUS$320.10k0.011%
€ 4.9m
Dennis Nally
Independent Director4.8yrsUS$375.36k0.0052%
€ 2.4m
Ornella Barra
Director9.8yrsno datano data
Henry McGee
Independent Director20yrsUS$320.10k0.0077%
€ 3.5m
Lorence Kim
Independent director2.1yrsUS$397.33k0.000090%
€ 41.5k
Redonda Miller
Independent Director1.8yrsUS$311.82k0.00080%
€ 369.0k

9.5yrs

Average Tenure

64yo

Average Age

Experienced Board: ABG's board of directors are considered experienced (9.5 years average tenure).